Hepatocellular carcinoma
Also known as: HCC, hepatoma, primary hepatocellular cancer, liver cell carcinoma
Hepatocellular carcinoma (HCC) is a primary hepatic malignancy typically developing secondary to chronic hepatitis or cirrhosis. Clinical management necessitates specialist staging, evaluation of hepatic reserve, and individualised oncological protocols, alongside antiviral therapy as indicated. Chinese medicine is limited to coordinated supportive care focused on symptom management and quality of life, rather than primary oncological control. Current evidence identifies observational prevention signals in chronic hepatitis B, but lacks proof of efficacy once malignancy is established [1]. While saikosaponin D research offers mechanistic hypotheses [3] and berberine–sorafenib data remain strictly preclinical, these do not support clinical co-prescription [4]. Cited evidence fails to establish acupuncture efficacy or validate the specific formulas listed for HCC, and some records provide insufficient detail for clinical inference [2].
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Abstain from alcohol consumption and engage in smoking cessation protocols where applicable.
- •Adhere to all prescribed antiviral and oncological regimens and maintain compliance with imaging, haematological monitoring, and specialist consultations.
- •Adhere to nutritional directives from a clinical dietitian; avoid fasting, non-clinical detoxification protocols, or restrictive dietary regimens intended for malignancy.
- •Balance low-intensity physical activity with sufficient rest, and maintain a clinical record of nutritional intake, body mass, symptom progression, and all supplementary agents for review.
Cautions & Contraindications
- •Do not add berberine to sorafenib on the basis of the supplied study: cell and mouse findings do not establish human benefit, dose, interaction risk or safety.[]
- •Do not use saikosaponin D products or Bupleurum-containing formulas to 'prime' immunotherapy outside appropriate specialist oversight; the review offers largely indirect preclinical hypotheses, not a validated clinical strategy.[]
- •Do not replace antiviral therapy, surveillance or cancer treatment with herbs. Prevention associations in selected chronic hepatitis B cohorts do not establish treatment benefit in existing HCC.[]
- •Defer needling with active bleeding, clinically significant coagulopathy, severe thrombocytopenia, febrile illness or severe neutropenia until the treating service clears it. These are procedural safety precautions; the supplied sources do not define safe blood-count thresholds or evaluate acupuncture safety.[]
When to reassess or seek care again
Agree on one or two supportive targets and review within 1–2 weeks: record nausea, fatigue, pain or sleep disturbance on consistent 0–10 scales, food intake, weight and functional ability. Interpret weight gain alongside possible fluid retention. Stop or modify adjunctive care if symptoms worsen or no meaningful benefit emerges over 2–4 weeks. New jaundice, increasing abdominal girth, persistent vomiting or falling intake warrants prompt medical review; emergency features require immediate escalation. Liver tests, blood counts and treatment-response assessment remain under the specialist team's plan.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Frontiers in immunology · 2026
- Liver international : official journal of the International Association for the Study of the Liver · 2026
- Frontiers in immunology · 2026
- Phytomedicine : international journal of phytotherapy and phytopharmacology · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
